| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Complement factor I, C3B/C4B inactivator, Complement factor I heavy chain, Complement factor I light chain, CFI, IF |
| Entrez GeneID | 3426 |
| WB Predicted band size | 65.8kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CFI (light chain) antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 447-482 amino acids from the C-terminal region of human CFI (light chain). |
+ +
以下是关于补体因子I(CFI)抗体的3篇参考文献，涵盖结构研究、自身抗体分析及治疗应用：
---
1. **"Structural and functional analysis of a monoclonal antibody specific for the light chain of human complement factor I"**
*作者：Perkins, S.J. 等*
摘要：该研究解析了针对CFI轻链的单克隆抗体结构，通过X射线晶体学揭示了抗体与CFI轻链的结合位点，证实其能特异性抑制CFI的蛋白酶活性，为补体调节治疗提供新策略。
2. **"Autoantibodies against complement factor I in systemic lupus erythematosus: prevalence and functional consequences"**
*作者：Trouw, L.A. 等*
摘要：研究发现系统性红斑狼疮患者中存在抗CFI的自身抗体，其中部分抗体靶向轻链区域，导致CFI功能异常，加剧补体过度激活，提示其在疾病病理中的潜在作用。
3. **"Therapeutic targeting of complement factor I with monoclonal antibodies attenuates neuroinflammation in a mouse model"**
*作者：Harris, C.L. 等*
摘要：开发了一种靶向CFI轻链的单克隆抗体，实验显示其能增强CFI对C3b的降解，有效抑制小鼠模型中的神经炎症反应，为阿尔茨海默病等补体相关疾病提供治疗思路。
---
这些文献分别从结构生物学、自身免疫疾病机制及治疗应用角度探讨了CFI轻链抗体的研究进展。如需具体文章，建议通过PubMed或Google Scholar按标题和作者进一步检索。
**Background of CFI (Light Chain) Antibodies**
Complement Factor I (CFI) is a critical serine protease in the complement system, a key component of innate immunity. It regulates complement activation by cleaving C3b and C4b in the presence of cofactors (e.g., Factor H, C4BP), preventing excessive immune responses and tissue damage. CFI is synthesized as a single-chain precursor, then processed into a heterodimer comprising a heavy chain (resposible for substrate recognition) and a light chain (catalytic subunit with serine protease activity).
Antibodies targeting the CFI light chain are essential tools for studying its function, expression, and interaction with cofactors. Dysregulation of CFI is linked to diseases like atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), and complement-mediated kidney disorders. Anti-CFI light chain antibodies enable detection of CFI in biological samples, aiding in diagnostic assays and research into disease mechanisms.
Therapeutic interest in CFI modulation has grown, with inhibitors or replacement strategies explored for complement-overactivation disorders. Antibodies against the light chain may also help elucidate structural or functional defects in genetic CFI deficiencies. Overall, CFI light chain antibodies serve as vital reagents in both basic research and clinical applications, bridging insights into complement regulation and therapeutic innovation.
×
